Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review
Top Cited Papers
- 1 January 2010
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 10 (1), 43-50
- https://doi.org/10.1016/s1473-3099(09)70325-1
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Extended-spectrum β-lactamase-producing organismsJournal of Hospital Infection, 2009
- The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infectionsInternational Journal of Antimicrobial Agents, 2009
- Oral and Parenteral Therapeutic Options for Outpatient Urinary Infections Caused byEnterobacteriaceaeProducing CTX-M Extended-Spectrum β-LactamasesAntimicrobial Agents and Chemotherapy, 2009
- Fosfomycin: Use Beyond Urinary Tract and Gastrointestinal InfectionsClinical Infectious Diseases, 2008
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Dissemination of Clonally RelatedEscherichia coliStrains Expressing Extended-Spectrum β-Lactamase CTX-M-15Emerging Infectious Diseases, 2008
- In vitro activity of β-lactam and non–β-lactam antibiotics in extended-spectrum β-lactamase–producing clinical isolates of Escherichia coliDiagnostic Microbiology and Infectious Disease, 2006
- Extended-Spectrum β-Lactamases: a Clinical UpdateClinical Microbiology Reviews, 2005
- Treatment of Uncomplicated Urinary Tract Infections in an Era of Increasing Antimicrobial ResistanceMayo Clinic Proceedings, 2004
- Fosfomycin TromethamineDrugs, 1997